In the wake of this sell-off, a critical question arises about whether LLY stock represents a buying opportunity.

Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors ...

Eli Lilly is seeing strong growth from its weight loss drugs. Investors are nervous about tariffs on drugs and weak data from ...

The stock is struggling badly, and if things don't improve in short order, Eli Lilly will be on track for its worst ...

Eli Lilly hiked its 2025 guidance and posted second-quarter earnings that topped estimates on strong demand for its blockbuster weight loss and diabetes drugs. The company also released long-awaited ...

Eli Lilly reported second quarter earnings Thursday, a day after competitor Novo Nordisk missed earnings estimates by Wall ...

The FDA says shortages of GLP-1s are over, but many patients are still getting what are essentially copied medications.

Eli Lilly and Company LLY will report its second-quarter earnings on Aug. 7, before market open. The Zacks Consensus Estimate ...